

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGES OF CHAIRMAN OF THE BOARD, CHAIRMAN OF THE NOMINATION COMMITTEE

The board of directors of the Company announces that, with effect from 3 December 2021:

- (1) Mr. Wang Chuncheng has resigned and ceased to be the Chairman of the Board, the non-executive Director and the Chairman of the Nomination Committee; and
- (2) Mr. Han Yuewei, currently an executive Director and the Chief Executive Officer of the Company, has been appointed as the Chairman of the Board and the Chairman of the Nomination Committee. He will remain as an executive Director, the Chief Executive Officer of the Company, the Chairman of the Executive Committee and a member of the Corporate Governance Committee.

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGES OF CHAIRMAN OF THE BOARD, CHAIRMAN OF THE NOMINATION COMMITTEE

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from 3 December 2021:

- (1) Mr. Wang Chuncheng (“**Mr. Wang**”) has resigned and ceased to be the Chairman of the Board, the non-executive Director and the Chairman of the nomination committee of the Company (the “**Nomination Committee**”) due to other work arrangements; and

- (2) Mr. Han Yuewei (“**Mr. Han**”), currently an executive Director and the Chief Executive Officer of the Company, has been appointed as the Chairman of the Board, the Chairman of the Nomination Committee. Mr. Han will remain as an executive Director, the Chief Executive Officer of the Company, the Chairman of the executive committee of the Company (the “**Executive Committee**”) and a member of the corporate governance committee of the Company (the “**Corporate Governance Committee**”).

Mr. Wang has confirmed that he has no disagreement with the Board and there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Wang for his invaluable contributions to the Group and the Board.

The biographical details of Mr. Han are set out as follows:

Mr. Han Yuewei, aged 53, currently serves as an executive vice president of China Resources (Holdings) Company Limited and has been appointed as an executive Director, Chief Executive Officer of the Company since October 2019. He also serves as the chairman of Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司)(the shares of which are listed on the Shenzhen Stock Exchange, Stock Code: 000423), and a director of China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司)(the shares of which are listed on the Shenzhen Stock Exchange (Stock Code: 000999)) and a director of China Resources Double-Crane Pharmaceutical Company Limited (華潤雙鶴藥業股份有限公司)(the shares of which are listed on the Shanghai Stock Exchange, Stock Code: 600062). Mr. Han served as an executive director of China Resources Medical Holdings Company Limited (“**CR Medical**”) (listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), stock code: 1515) from October 2017 to October 2019, during which he served as the chief executive officer of CR Medical and the general manager of China Resources Healthcare Group Limited, the controlling shareholder of CR Medical. Mr. Han worked for China Resources Land Limited (“**CR Land**”) (listed on the Stock Exchange, stock code: 1109) from October 2010 to October 2017, during which he served as deputy general manager of Shenyang Region, deputy general manager of Shenzhen Region, director of engineering and vice president of CR Land. Prior to joining CR Land, Mr. Han worked as the deputy director and director of the Bureau of Public Works of Shenzhen Municipality (深圳市建築工務署) from April 2002 to October 2010. Mr. Han obtained a master’s degree in construction economics and management from Tsinghua University (清華大學) and a bachelor’s degree in construction management from Tsinghua University in July 1993 and July 1991 respectively.

There is no service contract entered into between Mr. Han and the Company for his position as an executive Director. Mr. Han will be subject to retirement by rotation and re-election at the annual general meeting pursuant to the articles of association of the Company. Mr. Han will not receive any director's emolument from the Company.

As at the date of this announcement, Mr. Han beneficially owned 300,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**Securities and Futures Ordinance**"), representing less than 0.01% of the issued share capital of the Company. Saved as disclosed above, Mr. Han does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Han (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) currently does not hold any other position in the Company or any of its subsidiaries; (iii) did not hold any other directorship in public companies listed in Hong Kong or overseas in the last three years; (iv) does not have any other matters in relation to their appointments that need to be brought to the attention of the holders of the securities of the Company; and (v) there is no other information which is required to be disclosed pursuant to any requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

The Board hereby extends its gratitude to Mr. Han for his new appointment.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Code provision A.2.1 of the Corporate Governance Code as set out in Appendix 14 to the Listing Rules states that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Notwithstanding the deviation from code provision A.2.1, the Board believes that with the support of the management, vesting the roles of both chairman and chief executive officer by the same person can facilitate execution of the Group's business strategies and boost effectiveness of its operation. In addition, under the supervision by the Board which currently consists of three executive directors, four non-executive directors and four independent non-executive directors, the interest of the shareholders of the Company will be adequately and fairly represented.

By Order of the Board

China Resources Pharmaceutical Group Limited

Han Yuewei

Chairman

Jinan, 3 December 2021

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and executive Director, Mdm. Weng Jingwen and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mr. Tan Ying, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.